Courage to innovate
Change the future

OBI ‘s Proprietary Enzyme EndoSymeOBI™ Featured on Cover of Prestigious International Journal, JACS Au.

OBI Pharma’s proprietary enzyme, EndoSymeOBI™, recently being featured on the cover of the JACS Au. This recognition underscores the promising potential of the enzyme in the field of new drug development. OBI Pharma’s proprietary enzyme, EndoSymeOBI™, recently being featured on the cover of the JACS Au. This recognition underscores the promising potential of the enzyme […]

Dr. Heidi Wang, CEO of OBI Pharma, Inc., Selected as One of the Top 10 Managers of High-performing Enterprises by the Golden Torch Award

Taipei, Taiwan – The Golden Torch Award, a prestigious program that honors outstanding corporate leaders, announced today (June 21) that Dr. Heidi Wang, CEO of OBI Pharma, Inc. (4174.two), has been selected as one of the “Top 10 Managers of High-performing Enterprises”. Dr. Wang holds a Ph.D. in Molecular Biology and Virology from the University […]

OBI Pharma shareholders’ meeting launches new company strategy and embraces transformation 

Strong emphasis on developing ADC assets and technology platform and encouraging global collaborations and partnership   OBI PHARMA, INC. (4174 TWO ) has undergone meaningful transformation over the past year. From pipeline refresh, organizational restructuring, to cultural revitalization, the company’s commitment to innovation is evident. Dr. Heidi Wang, CEO of OBI, emphasizes that this transformation […]

OBI Pharma announces Phase 1/2 study initiation for OBI-992, a TROP2-targeted antibody drug-Conjugate (ADC) for cancer therapy

Clinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors. TAIPEI, Taiwan, June 12, 2024, ─ OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface antigen 2), an antigen overexpressed in multiple tumor […]

2024 Annual Shareholders’ Meeting

OBI Pharma at BIO USA 2024

OBI showcased its proprietary ADC platform GlycOBI™ and attracted significant interest from the audience significant interest from the audience On June 4th, OBI Pharma from Taiwan made a notable appearance at BIO USA 2024. The company introduced its proprietary ADC (Antibody-Drug Conjugate) technology platform, GlycOBI™, which quickly garnered significant interest. This platform enables site-specific conjugation […]

2024 ASCO Annual Meeting

Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform

Title: OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models Abstract presentation number: 1893 / Poster number 23/4 PDF LINK Title: In vitro characterization of a novel TROP2-targeting antibody-drug conjugate OBI-992 Abstract presentation number: 3130 / Poster number 21/11 PDF LINK Title: Development of a novel site-specific ADC glycan […]

Adagloxad Simolenin (OBI-822)/OBI-821, receives a positive 1st interim analysis recommendation, suggesting the continuation of the Phase III TNBC trial

1.Date of occurrence of the event:2024/01/31 2.New drug name or code: The active cancer immunotherapy Adagloxad Simolenin (OBI-822)/OBI-821 3.Indication: Adagloxad Simolenin (OBI-822) is a therapeutic cancer vaccine classified as an active cancer immunotherapy. Globo H-KLH conjugate triggers immune response against hard-to-treat cancers once injected into the human system. OBI-821 is an adjuvant that is mixed […]

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

First clinical trial to evaluate the safety and efficacy of OBI-992, a novel antibody –  drug conjugate (ADC) targeting TROP2. Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024. OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an […]